Abstract

Objective To investigate the clinical effect and safety of singulair combined with budesonide in the treatment of cough variant asthma. Method 120 cases of cough variant asthma treated at our hospital from January, 2015 to December, 2016 were chosen and randomly divided into a treatment and a control group, 60 for each group. Both groups took routine and symptomatic treatment, including relieving cough and reducing sputum, anti-infection, and inhaling budesonide. In addition, the treatment group orally took montelukast. The clinical effects and symptom-relieving times were compared between these two groups. Results The total efficacy was obviously higher in then observation group than in the control group (91.7% vs. 78.3%) (P 0.05). Conclusion Montelukast sodium combined with budesonide for children with cough variant asthma is clinically effective and safe, so it is a good choice. Key words: Budesonide; Montelukast; Cough variant asthma

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call